New and revisited approaches to preserving the reperfused myocardium

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Pharmacology

Background:

• Early reperfusion in ST-elevation myocardial infarction (STEMI) improves outcomes but high morbidity and mortality persist.
• Key issues include impaired cardiac pump function due to rapid muscle infarction and adverse left ventricular remodelling post-STEMI.
• Current strategies to reduce infarct size beyond reperfusion have yielded disappointing results, necessitating new therapeutic approaches.

Purpose of the Study:

• To review emerging therapies for preserving reperfused myocardium in STEMI patients.
• To discuss strategies targeting cellular mechanisms and pharmacological agents for cardioprotection.
• To explore treatments for the no-reflow phenomenon and its impact on cardiac healing and remodelling.

Main Methods:

• Literature review of current research on myocardial protection post-reperfusion.
• Analysis of therapeutic targets including mitochondrial bioenergetics, pyroptosis, and autophagy.
• Evaluation of inhaled anaesthetics and treatments for the no-reflow phenomenon.

Main Results:

• Several promising therapeutic avenues are being explored to protect the heart during and after myocardial infarction.
• Targeting cellular pathways like mitochondrial function and programmed cell death shows potential for reducing myocardial damage.
• Inhaled anaesthetics and interventions for no-reflow may mitigate adverse cardiac remodelling.

Conclusions:

• Despite advances in reperfusion therapy, significant unmet needs remain in managing STEMI.
• Novel therapeutic strategies targeting cellular protection and addressing the no-reflow phenomenon are essential for improving long-term outcomes.
• Further research into these approaches holds promise for reducing mortality and morbidity in STEMI patients.